Register Login

VIR BIOTECHNOLOGY, INC. (VIR)

Director Coughlin Timothy 🟢 acquired 48.0K shares (2 derivative) of Vir Biotechnology, Inc. (VIR) at $8.51 Transaction Date: Jun 09, 2026 | Filing ID: 042326

Full text
Register to leave comments
  • News bot June 10, 2026, 10:22 p.m.

    🔍 Coughlin Timothy (Director)

    Company: Vir Biotechnology, Inc. (VIR)

    Report Date: 2026-06-09

    Transaction Summary:

    • Total transactions: 4
    • Derivative instruments: 2
    • Holdings reported: 0
    • Total shares acquired: 48,000

    Detailed Transactions and Holdings:

    • Acquired 8,000 shares of Common Stock (Direct)
      Date: 2026-06-09 | Code: A | equity_swap_involved: 0 | shares_owned_after: 8,000.00 | transaction_form_type: 4 | Footnotes: F1, F2
    • Acquired 8,000 shares of Common Stock (Direct)
      Date: 2026-06-09 | Code: A | equity_swap_involved: 0 | shares_owned_after: 16,000.00 | transaction_form_type: 4 | Footnotes: F1, F3
    • Acquired 16,000 shares of Stock Option (Right to Buy) at $8.51 per share (Derivative)
      Date: 2026-06-09 | Code: A | Expires: 2036-06-08 | equity_swap_involved: 0 | shares_owned_after: 16,000.00 | transaction_form_type: 4 | Footnotes: F4
    • Acquired 16,000 shares of Stock Option (Right to Buy) at $8.51 per share (Derivative)
      Date: 2026-06-09 | Code: A | Expires: 2036-06-08 | equity_swap_involved: 0 | shares_owned_after: 16,000.00 | transaction_form_type: 4 | Footnotes: F5

    Footnotes:

    • F1: Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan.
    • F2: 1/3 of the RSUs will vest on June 9, 2027, and the remaining RSUs will vest in two equal annual installments thereafter.
    • F3: The RSUs will vest in full on the earlier of (i) June 9, 2027, or (ii) the date of the Issuer's next annual meeting of stockholders.
    • F4: 1/3 of the shares subject to the stock option will vest and become exercisable on June 9, 2027, and the remaining shares will vest and become exercisable in 24 equal monthly installments thereafter.
    • F5: The shares subject to the stock option vest and become exercisable in full on the earlier of (i) June 9, 2027, or (ii) the date of the Issuer's next annual meeting of stockholders.

Search

News categories